Sanjeev Deva

机构：University of Auckland, Auckland City Hospital · ORCID：0000-0002-7933-303X

发表论文 91 篇 · 总被引 616 次 · h-index 14

代表论文

• Single-Agent Divarasib in Patients With KRAS G12C –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study (2025 · Journal of Clinical Oncology · 被引 30)
• Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma (2024 · EBioMedicine · 被引 17)
• OA14.06 Divarasib Single-Agent Long-Term Follow-up and Atezolizumab Combination Treatment in Patients with KRAS G12C-Positive NSCLC (2024 · Journal of Thoracic Oncology · 被引 7)
• A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results (2025 · Cancer Chemotherapy and Pharmacology · 被引 5)
• Blending space and time to talk about cancer in extended reality (2024 · npj Digital Medicine · 被引 5)
• Abstract CT022: Divarasib plus migoprotafib combination treatment in patients with KRAS G12C-positive non-small cell lung cancer (NSCLC) (2025 · Cancer Research · 被引 3)